Can you support CaringBridge during our March campaign? Generous donors like you ensure that CaringBridge remains ad-free, private and protected.
Mar 10, 2018
Emma was diagnosed with metastatic Osteosarcoma~ July 8, 2009...
In April 2009, Emma complained of pain in his left leg above the knee. She had been skiing and cycling alot, so we thought this was an orthopedic issue. We took Emma to the orthopedic surgeon for x-rays & nothing was found. 4 wks. of physical therapy, ice, and ibuprofin were prescribed, then an MRI if pain hadn't dissipated. Pain decreased, so we thought p.t. was helping; in fact, a tumor had broken out of the bone, which can relieve pain. 3 wks. after seeing the orthopedist, at a routine visit to the pediatrician, Emma was advised to get the MRI. On July 6th, the scan revealed a mass in her left distal femur; within 2 hours she was admitted to CHLA. At the age of 13, on July 8, 2009, Emma was diagnosed with metastatic osteosarcoma (bone cancer). A single, marble-sized tumor was also found and removed by thoracoscopy from his left lung. Emma completed 6 MAP treatments, then had surgery to remove the tumor on her leg on October 2, 2009. The femur was replaced with a Compress prosthesis and artificial knee. Pathology was 75% necrosis; clear margins. 18 total chemo treatments were completed Feb. 28, 2010, with no evidence of disease (NED).
June, 2010, Emma had a boating accident at camp. July 5, 2010 he had a complete revision of the prosthesis (July 5, 2010).
September 14, 2010 6 mo. scans revealed a tumor in upper left lung. Sept. 20, 2010- thoracotomy; total of 4 tumors found, 3 in the pleural cavity; clear margins. Treatment consisted of 10 rounds chemo (Ifosfomide, Etoposide), the trial drug L-MTP-PE, and radiation to the lung. Completed: May 15, 2011- Ifos/ Etop; June 24, 2011- radiation; & L-MTP-PE- June 28, 2011.
July 16, 2012- 15 mo. scans reveal 2 cm. tumor in lower right lung. July 22, 2012- thorocotomy; 2 tumors found; lobectomy of lower right lung; clear margins. Gemcitabine/Docetaxel completed January 2013.
February 2013 began Hu3F8/IL-2 trial at MSKCC in New York.
We can't begin to express our gratitude for all the messages of support we've received!